secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-10-14T12:35:20+00:00
Accession:  0001628280-26-065826
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Vir Bio, Gilead sign solid-tumor TCE deal: $90M upfront, up to $1.74B milestones
--------------------------------------------------------------------------------

- Gilead to pay $90M upfront ($65M cash plus $25M equity at a 30% premium) and up to $45M in near-term preclinical milestones, totaling up to $135M.
- Vir eligible for up to $1.74B in development, regulatory and commercial milestones plus tiered high single-digit to low double-digit royalties on net sales.
- Deal covers three novel PRO-XTEN dual-masked T-cell engager candidates targeting selected solid tumor-associated antigens, with Gilead holding an exclusive license.
- Gilead to buy 1,765,486 VIR shares at $14.16/share (~$25M) under a Stock Purchase Agreement with 1-year standstill, voting and lockup provisions.
- Vir handles discovery, design and optimization; Gilead leads development, manufacturing and commercialization. Vir's second PRO-XTEN collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/0001628280-26-065826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/vir-20261009.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-065826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer